479 related articles for article (PubMed ID: 22170975)
1. Clofarabine in the treatment of newly diagnosed acute myeloid leukemia in older adults.
Tran H; Yang D
Ann Pharmacother; 2012 Jan; 46(1):89-96. PubMed ID: 22170975
[TBL] [Abstract][Full Text] [Related]
2. European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy.
Burnett AK; Russell NH; Kell J; Dennis M; Milligan D; Paolini S; Yin J; Culligan D; Johnston P; Murphy J; McMullin MF; Hunter A; Das-Gupta E; Clark R; Carr R; Hills RK
J Clin Oncol; 2010 May; 28(14):2389-95. PubMed ID: 20385984
[TBL] [Abstract][Full Text] [Related]
3. The role of Clofarabine in the treatment of adults with acute myeloid leukemia.
Fozza C
Crit Rev Oncol Hematol; 2015 Mar; 93(3):237-45. PubMed ID: 25457773
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors.
Kantarjian HM; Erba HP; Claxton D; Arellano M; Lyons RM; Kovascovics T; Gabrilove J; Craig M; Douer D; Maris M; Petersdorf S; Shami PJ; Yeager AM; Eckert S; Abichandani R; Faderl S
J Clin Oncol; 2010 Feb; 28(4):549-55. PubMed ID: 20026805
[TBL] [Abstract][Full Text] [Related]
5. Clofarabine: a new treatment option for patients with acute myeloid leukemia.
Larson ML; Venugopal P
Expert Opin Pharmacother; 2009 Jun; 10(8):1353-7. PubMed ID: 19463072
[TBL] [Abstract][Full Text] [Related]
6. A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia.
Jabbour E; Short NJ; Ravandi F; Huang X; Xiao L; Garcia-Manero G; Plunkett W; Gandhi V; Sasaki K; Pemmaraju N; Daver NG; Borthakur G; Jain N; Konopleva M; Estrov Z; Kadia TM; Wierda WG; DiNardo CD; Brandt M; O'Brien SM; Cortes JE; Kantarjian H
Cancer; 2017 Nov; 123(22):4430-4439. PubMed ID: 28708931
[TBL] [Abstract][Full Text] [Related]
7. Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia.
Nazha A; Kantarjian H; Ravandi F; Huang X; Choi S; Garcia-Manero G; Jabbour E; Borthakur G; Kadia T; Konopleva M; Cortes J; Ferrajoli A; Kornblau S; Daver N; Pemmaraju N; Andreeff M; Estrov Z; Du M; Brandt M; Faderl S
Am J Hematol; 2013 Nov; 88(11):961-6. PubMed ID: 23877926
[TBL] [Abstract][Full Text] [Related]
8. Clofarabine does not negatively impact the outcomes of patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation.
Mathisen MS; Kantarjian H; Jabbour E; Garcia-Manero G; Ravandi F; Faderl S; Borthakur G; Cortes JE; Quintás-Cardama A
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):139-43. PubMed ID: 23276886
[TBL] [Abstract][Full Text] [Related]
9. Clofarabine for the treatment of adult acute myeloid leukemia.
Thomas X; Raffoux E; Elhamri M; Lobe I; Cannas G; Dombret H
Future Oncol; 2009 Oct; 5(8):1197-210. PubMed ID: 19852733
[TBL] [Abstract][Full Text] [Related]
10. Clofarabine in the treatment of poor risk acute myeloid leukaemia.
Krawczyk J; Ansar N; Swords R; Murphy T; MacDonagh B; Meenaghan T; Hayden P; Hayad A; Murray M; O'Dwyer M
Hematol Oncol; 2010 Sep; 28(3):118-23. PubMed ID: 19768694
[TBL] [Abstract][Full Text] [Related]
11. Clofarabine in the treatment of acute myeloid leukemia in older adults.
Tiley S; Claxton D
Ther Adv Hematol; 2013 Feb; 4(1):5-13. PubMed ID: 23610610
[TBL] [Abstract][Full Text] [Related]
12. Clofarabine in the treatment of elderly patients with acute myeloid leukemia.
Aleem A; Anjum F; Algahtani F; Iqbal Z; Alsaleh K; Almomen A
Asian Pac J Cancer Prev; 2013; 14(2):1089-92. PubMed ID: 23621192
[TBL] [Abstract][Full Text] [Related]
13. Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients.
Faderl S; Ravandi F; Huang X; Wang X; Jabbour E; Garcia-Manero G; Kadia T; Ferrajoli A; Konopleva M; Borthakur G; Burger J; Feliu J; Kantarjian HM
Cancer; 2012 Sep; 118(18):4471-7. PubMed ID: 22282348
[TBL] [Abstract][Full Text] [Related]
14. Low efficacy and high mortality associated with clofarabine treatment of relapsed/refractory acute myeloid leukemia and myelodysplastic syndromes.
Roberts DA; Wadleigh M; McDonnell AM; DeAngelo DJ; Stone RM; Steensma DP
Leuk Res; 2015 Feb; 39(2):204-10. PubMed ID: 25554239
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial to assess the safety and efficacy of clofarabine in combination with low-dose cytarabine in elderly patients with acute myeloid leukemia.
Martínez-Cuadrón D; Montesinos P; Oriol A; Salamero O; Vidriales B; Bergua J; Herrera P; Vives S; Sanz J; Carpio C; Rodríguez-Veiga R; Moscardó F; Sanz MA
Ann Hematol; 2014 Jan; 93(1):43-6. PubMed ID: 24081577
[TBL] [Abstract][Full Text] [Related]
16. Cytarabine and clofarabine after high-dose cytarabine in relapsed or refractory AML patients.
Scappini B; Gianfaldoni G; Caracciolo F; Mannelli F; Biagiotti C; Romani C; Pogliani EM; Simonetti F; Borin L; Fanci R; Cutini I; Longo G; Susini MC; Angelucci E; Bosi A
Am J Hematol; 2012 Dec; 87(12):1047-51. PubMed ID: 23151979
[TBL] [Abstract][Full Text] [Related]
17. Treatment of molecular relapse in patients with acute myeloid leukemia using clofarabine monotherapy.
Racil Z; Toskova M; Dvorakova D; Jeziskova I; Razga F; Buresova L; Timilsina S; Mayer J
Am J Hematol; 2012 Feb; 87(2):211-3. PubMed ID: 22052688
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML.
Löwenberg B; Pabst T; Maertens J; van Norden Y; Biemond BJ; Schouten HC; Spertini O; Vellenga E; Graux C; Havelange V; de Greef GE; de Weerdt O; Legdeur MJ; Kuball J; Kooy MV; Gjertsen BT; Jongen-Lavrencic M; van de Loosdrecht AA; van Lammeren-Venema D; Hodossy B; Breems DA; Chalandon Y; Passweg J; Valk PJ; Manz MG; Ossenkoppele GJ;
Blood; 2017 Mar; 129(12):1636-1645. PubMed ID: 28049642
[TBL] [Abstract][Full Text] [Related]
19. A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome.
Faderl S; Ravandi F; Huang X; Garcia-Manero G; Ferrajoli A; Estrov Z; Borthakur G; Verstovsek S; Thomas DA; Kwari M; Kantarjian HM
Blood; 2008 Sep; 112(5):1638-45. PubMed ID: 18565853
[TBL] [Abstract][Full Text] [Related]
20. G-CSF priming, clofarabine, and high dose cytarabine (GCLAC) for upfront treatment of acute myeloid leukemia, advanced myelodysplastic syndrome or advanced myeloproliferative neoplasm.
Becker PS; Medeiros BC; Stein AS; Othus M; Appelbaum FR; Forman SJ; Scott BL; Hendrie PC; Gardner KM; Pagel JM; Walter RB; Parks C; Wood BL; Abkowitz JL; Estey EH
Am J Hematol; 2015 Apr; 90(4):295-300. PubMed ID: 25545153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
